Showing results (341-350 of 458) with videos related to

Sort By:
Pageof 46
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 16, 2012
Dose escalation study of no-carrier-added 131I-metaiodobenzylguanidine for relapsed or refractory neuroblastoma: new approaches to neuroblastoma therapy consortium trialKatherine K Matthay, Brian Weiss, Judith G Villablanca, et al.
Nature Communications|September 20, 2017
Common variants in MMP20 at 11q22.2 predispose to 11q deletion and neuroblastoma riskXiao Chang, Yan Zhao, Cuiping Hou, et al.
Molecular Cancer Therapeutics|February 5, 2025
Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastomaSmita Matkar, Michael P East, Timothy J Stuhlmiller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.
Genes & Development|March 13, 2008
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressorSusanne Schlisio, Rajappa S Kenchappa, Liesbeth C W Vredeveld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2018
Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk <i>MYCN</i>-Not-Amplified Human NeuroblastomaJun S Wei, Igor B Kuznetsov, Shile Zhang, et al.
Frontiers in Immunology|July 4, 2018
A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
Frontiers in Immunology|July 27, 2018
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931M Fevzi Ozkaynak, Andrew L Gilman, Wendy B London, et al.
British Journal of Cancer|September 15, 2012
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG projectG Schleiermacher, V Mosseri, W B London, et al.
Genome Research|August 16, 2020
Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastomaGonzalo Lopez, Karina L Conkrite, Miriam Doepner, et al.
Pageof 46